Linsitinib, a novel and highly selective dual inhibitor of IGF-1R and insulin receptors, may reduce local inflammatory responses by promoting Treg differentiation and/or activation and reducing TNF-α levels in a mouse model of TAO (90). This evidence concerns the gene IGF1R and thromboangiitis obliterans.